ETTX Nasdaq

Entasis Therapeutics Holdings Inc.

ETTX | $2.19 -0.46% 0.46%

(0.0% 1d) (-0.2% 1m) (0.0% 1y) (-0.2% 2d) (0.2% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2022-08-03
Market Cap: $ 104,795,396
http://www.entasistx.com
Sec Filling | Patents | 47 employees

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.

batteries battery msa antibacterial injection

add to watch list Paper trade email alert is off

Press-releases

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics
Published: 2023-02-01 (Crawled : 23:00) - ir.vtvtherapeutics.com
VTVT | $24.975 2.21% 0.35% 4.4K

Health Technology

| 2590.65% | O: 1.25% H: 3.19% C: 1.06%
therapeutics

Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022
Published: 2022-10-19 (Crawled : 16:00) - biospace.com/
INVA | $15.17 1.61% 1.52% 1.5M

Health Technology

| 10.97% | O: 0.15% H: 0.29% C: -1.97%
trial therapeutics

La Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) to be Presented at IDWeek 2022
Published: 2022-10-14 (Crawled : 22:00) - biospace.com/
INVA | $15.17 1.61% 1.52% 1.5M

Health Technology

| 13.46% | O: 0.6% H: 1.38% C: -1.64%
xerava wholly

Innoviva Completes Acquisition of Entasis Therapeutics
Published: 2022-07-11 (Crawled : 14:20) - biospace.com/
INVA | $15.17 1.61% 1.52% 1.5M

Health Technology

| 3.62% | O: 1.16% H: 0.0% C: 0.0%
acquisition therapeutics

Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.
Published: 2022-07-08 (Crawled : 13:00) - biospace.com/
INVA | $15.17 1.61% 1.52% 1.5M

Health Technology

| 1.34% | O: -2.2% H: 0.0% C: 0.0%
ETTX | $2.19 -0.46% 0.46%

Health Technology

| -0.23% | O: -0.23% H: 0.0% C: 0.0%
therapeutics

Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference
Published: 2022-06-09 (Crawled : 12:20) - globenewswire.com
ETTX | $2.19 -0.46% 0.46%

Health Technology

| 0.23% | O: 0.0% H: 0.0% C: -0.46%
etx0462 conference therapeutics

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Entasis Therapeutics Holdings Inc.
Published: 2022-05-24 (Crawled : 23:00) - prnewswire.com
INVA | $15.17 1.61% 1.52% 1.5M

Health Technology

| -1.88% | O: -0.84% H: 1.96% C: -2.02%
ETTX | $2.19 -0.46% 0.46%

Health Technology

| 0.23% | O: -0.46% H: 0.46% C: 0.46%
acquisition therapeutics

Investor Alert - The M&A Class Action Firm Announces an Investigation of Entasis Therapeutics Holdings Inc. - ETTX
Published: 2022-05-24 (Crawled : 01:00) - prnewswire.com
INVA | $15.17 1.61% 1.52% 1.5M

Health Technology

| -8.97% | O: -3.51% H: 0.0% C: -3.86%
ETTX | $2.19 -0.46% 0.46%

Health Technology

| 1.15% | O: 0.0% H: 0.92% C: 0.92%
therapeutics

Innoviva to Acquire Entasis Therapeutics
Published: 2022-05-23 (Crawled : 15:00) - biospace.com/
MC | $54.6 2.59% 0.73% 610K

Finance

| 24.01% | O: 0.61% H: 1.39% C: 0.5%
INVA | $15.17 1.61% 1.52% 1.5M

Health Technology

| -6.88% | O: 2.3% H: 0.0% C: 0.0%
ETTX | $2.19 -0.46% 0.46%

Health Technology

| 21.94% | O: 20.56% H: 0.0% C: 0.0%
therapeutics

Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference
Published: 2022-05-17 (Crawled : 17:00) - biospace.com/
ETTX | $2.19 -0.46% 0.46%

Health Technology

| 25.43% | O: 1.71% H: 1.69% C: -0.56%
conference trial therapeutics phase 3

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001140361-22-025957	4	2022-07-14	2022-07-11	Buy	P	7598814	29270476
0001140361-22-025957	4	2022-07-14	2022-07-08	Buy	P	11671662	21671662